Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 144

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 144
---
 the prefrontal cortex and mesolimbic dopamine pathways, areas involved in emotion control, reward, and food intake. Previous studies have shown that stimulation of the serotonergic system induces weight reduction and decreases food intake. Moreover, cerebral 5-HT2A binding was significantly and positively correlated with BMI and provided a predictive value for weight loss after gastric bypass surgery. Importantly, psychedelics may offer a unique approach to addressing both addiction and obesity, by disrupting rigid behavioral patterns, promoting cognitive flexibility, and increasing neuronal plasticity. Other Application Markets We are currently in the discovery phase of additional innovative molecules, that will potentially address the following markets Anxiety Disorder Overview Although anxiety is considered a common aspect of life, anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time. Anxiety disorders can present with a range of symptoms and may impact personal health as well as both social and professional interactions. Furthermore, it is common for those suffering with an anxiety disorder to also have co-occurring mental health disorders or physical illness, which can compound symptoms and complicate recovery. For example, it is estimated that half of patients diagnosed with depression also suffer from an anxiety disorder. There are several types of anxiety disorders, including generalized anxiety disorder, or GAD, social anxiety disorder and panic disorder, which are distinct but share common symptoms. In the aggregate, anxiety disorders are considered to be the most common mental illness in the United States, affecting approximately 40 million adults, or 18% of the population. Anxiety disorders are generally treated with medication, psychotherapy or both. Treatment often involves the use of antidepressants, including SSRIs, such as paroxetine, sertraline and citalopram. However, SSRIs typically have a slow onset of action and have a number of side effects, such as sexual dysfunction, drowsiness and weight gain. Benzodiazepines are also used to treat anxiety and can offer rapid reduction of symptoms, but their long-term use is associated with the development of tolerance, respiratory depression, drug dependence and sedative side effects. Finally, benzodiazepines have been noted to exacerbate the respiratory depression associated with opioids, thus contributing to the mortality associated with OUD. We are aware of several biopharmaceutical companies with psychedelic therapies in development for anxiety disorders including MAPS, Cybin, Incannex and MindMed. Post-Traumatic Stress Disorder Background PTSD is a psychiatric disorder that affects app approximately 6% of the U.S.